Wall Street

Should Twist Bioscience Investors Prepare for Disappointment?

Published by
The Street

By Maxx Chatsko Shares of the synthetic biology leader have defied gravity. That could change after the next quarterly results are released. Shares of investor favorite Twist Bioscience (TWST) – Get Twist Bioscience Corporation Report have declined 43% since the beginning of the year through the end of July. They still might be overvalued. The company, a leader in DNA synthesis for biotech researchers, deserves to trade at a premium. The size of the current premium may be questionable. If the business achieves fiscal full-year 2022 revenue of $200 million, then the current market cap would equ…

Read More

Share this Story
Load More Related Articles
Load More In Wall Street